Brand tirzepatide
Sold by Claya · Injection, pen · every brand tirzepatide record
What you actually pay
Per month
$1,458
| Medication · Mounjaro® Pen | $1,399 |
|---|---|
| Required membership | $59 |
Added from the figures recorded below.
Price
| Term | Per month | Charged today |
|---|---|---|
| Mounjaro® Pen “Mounjaro® Pen As low as $ 1,399 /month” | Per month$1,399 | Charged today$1,399 |
We earn nothing from this link. Claya has no commercial arrangement with Treatment Registry, and its record here is kept to the same standard as every other.
History
One reading so far. A price history appears here after the next verification pass.
- September 2, 2026 — Entry added to the register
Sourcing and terms
| States | All 50 states |
|---|---|
| Cancellation | “You may cancel your Subscription Service at any time for any reason.” |
| Membership | Required. $59 per month. “Claya membership starts at $59 per month.” |
Not yet checked: pharmacy, prescriber and consult fee.
Recorded from claya.com. Unlike the price rows above, these carry a summary rather than a word-for-word quotation, so they are not shown in quotation marks.
Notes
- 1. September 2, 2026 — Two different price schedules appear for the same products: the homepage banner lists Semaglutide 'as low as $149 /mo' and Tirzepatide 'Starting at $199 a month', while the dedicated Semaglutide product page lists 'As low as $179 /mo' and describes prescription medication as one of the included items at that price. Separately, the weight-loss FAQ states 'Claya membership starts at $59 per month' and explicitly 'your medication is not included in the membership fee' -- which membership figure relates to the $179/$149/$199 product prices is not stated anywhere in the fetched text, so the $59 figure is recorded only under `membership` and the product-page/homepage figures are recorded as `prices`. Claya explicitly does not accept insurance ('Claya does not accept commercial health insurance plans... you are obtaining products and services on a cash-pay basis'), so all prices above are cash prices. States: the blanket 'all fifty states' claim is qualified by a Louisiana carve-out specific to compounded GLP-1s ('due to applicable laws of the State of Louisiana, our third-party partner pharmacies cannot provide compounded GLP-1 medications to residents of the State of Louisiana' -- paraphrased from terms-of-use, original has a typo 'PRTNER').
Treatment Registry is an independent editorial record. It is not a government registry, a licensing body, or a certification. An entry means we recorded what a company published on a given date. It does not mean we recommend the program, and it does not mean the program is approved by anyone.